Shield Therapeutics PLC Results of 2021 Annual General Meeting (2902C)
June 17 2021 - 8:30AM
UK Regulatory
TIDMSTX
RNS Number : 2902C
Shield Therapeutics PLC
17 June 2021
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Results of 2021 Annual General Meeting
London, UK, 17 June 2021: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Feraccru (R) /Accrufer(R)
(ferric maltol), announces the results of the voting for each of
the resolutions as set out in the Notice of Annual General Meeting
2021. The Board reports that resolutions 1 to 10 passed as ordinary
resolutions and resolutions 11 and 12 were passed as special
resolutions, full details are shown below.
The following table shows the votes cast on each resolution:
VOTES FOR % VOTES AGAINST % VOTES WITHELD
Resolution 1 115,096,905 99.94 6,544 0.01 883,488
------------ ------ -------------- ----- --------------
Resolution 2 115,083,904 99.2 866,271 0.75 36,762
------------ ------ -------------- ----- --------------
Resolution 3 115,083,904 99.2 866,271 0.75 36,762
------------ ------ -------------- ----- --------------
Resolution 4 115,927,366 99.93 25,810 0.02 36,761
------------ ------ -------------- ----- --------------
Resolution 5 115,086,905 99.2 866,271 0.75 36,761
------------ ------ -------------- ----- --------------
Resolution 6 115,082,443 99.2 867,732 0.75 36,762
------------ ------ -------------- ----- --------------
Resolution 7 115,083,904 99.2 866,271 0.75 36,762
------------ ------ -------------- ----- --------------
Resolution 8 115,114,781 99.2 866,695 0.75 5,461
------------ ------ -------------- ----- --------------
Resolution 9 115,956,508 99.93 27,207 0.02 3,222
------------ ------ -------------- ----- --------------
Resolution 10 115,905,527 99.91 47,834 0.04 33,576
------------ ------ -------------- ----- --------------
Resolution 11 115,719,269 99.75 228,432 0.2 39,236
------------ ------ -------------- ----- --------------
Resolution 12 114,882,135 99.03 1,065,566 0.92 39,236
------------ ------ -------------- ----- --------------
Notes:
1. Number of shares in issue 215,837,965.
2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/ .
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0)19 1511 8500
Lucy Huntington-Bailey (General
Counsel and Company Secretary)
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product
Feraccru(R) /Accrufer(R) (ferric maltol), a novel, stable, non-salt
based oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s. The
Group plans to launch Accrufer(R) in the US during 2021 through a
highly experienced sales and marketing team. Feraccru(R) is already
being commercialised in the UK and European Union by Norgine B.V.,
who also have the marketing rights in Australia and New Zealand.
Shield also has an exclusive licence agreement with Beijing
Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong,
Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGMZGMVFNLGMZM
(END) Dow Jones Newswires
June 17, 2021 09:30 ET (13:30 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024